The FDA has approved Ascendis’ Yorvipath, a hormone replacement therapy to treat hypoparathyroidism. Ascendis was ready to bring the drug to the market 15 months ago but was rejected due to a manufacturing problem. Then 3 months ago things were delayed when the FDA said they needed additional time to make its decision. Initial supplies should be available in the first quarter of 2025.
Click here to read the entire article.